On August 11, 2022, a delegation of leaders from the Biologics Division of the Pharmaceutical and Biological Invention Examination Department of the National Intellectual Property Administration—including Inspector Pan Aiqun and Director Zhou Xia—paid a visit to Minhai Bio to conduct on-site research and provide guidance. The company’s Deputy General Manager, Mr. Huang, received the visiting delegation.

This morning, a symposium on the theme of “Vaccine Technology Innovation and Patent Management” was held in the company’s First Conference Room. Attending were General Manager Huang, General Manager Sun, all members of the Public Affairs and Research Management Department, as well as project leaders and key research personnel from the R&D Center. During the meeting, participants engaged in lively discussions and exchanges regarding challenges encountered in the patent application and examination processes for technologies such as mRNA vaccines, multivalent combination vaccines, and novel adjuvants. Leaders from the Biologics Division provided in-depth analysis and detailed guidance on the practical issues the company faces in its patent‑filing efforts.

In the afternoon, accompanied by General Manager Nie, the leaders of the Biologics Division visited the production facilities for inactivated poliovirus vaccine and pertussis component vaccine.

      During this fact-finding mission, the leadership of the Biologics Division fully commended Minhai Bio’s achievements in vaccine technology innovation and intellectual property protection, while offering valuable guidance that has played a constructive role in advancing the company’s innovative development and enhancing its capacity to leverage and safeguard intellectual property.